4.7 Article

N-Terminal Pro-B-Type Natriuretic Peptide in the Emergency Department The ICON-RELOADED Study

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 71, Issue 11, Pages 1191-1200

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2018.01.021

Keywords

acute heart failure; biomarker; diagnosis; NT-proBNP; prognosis

Funding

  1. Roche Diagnostics, Inc.
  2. Hutter Family Professorship
  3. Abbott
  4. Cleveland Heart Labs
  5. Siemens
  6. Singulex
  7. Prevencio
  8. Roche Diagnostics
  9. Siemens Healthcare Diagnostics
  10. Beckman Coulter
  11. Spingotech
  12. Ortho Clinical Diagnostics
  13. Patient-Centered Outcomes Research Institute
  14. National Institutes of Health
  15. Alere
  16. Roche
  17. Portola
  18. Trinity
  19. National Heart, Lung, and Blood Institute
  20. National Institute on Minority Health and Health Disparities
  21. Amgen
  22. Bristol-Myers Squibb
  23. Novartis
  24. Trevena
  25. Edwards Lifesciences
  26. Cardiorentis
  27. Alere/Biosite
  28. Boehringer Ingelheim
  29. Thermo Fisher
  30. Nanosphere
  31. Radiometer
  32. American Heart Association
  33. Agency for Healthcare Research and Quality
  34. Banyan
  35. Janssen
  36. Pfizer
  37. Medicines Company
  38. ZS Pharma
  39. Clark Fund for Cardiac Research Innovation
  40. Ortho Clinical

Ask authors/readers for more resources

BACKGROUND Contemporary reconsideration of diagnostic N-terminal pro-B-type natriuretic peptide (NT-proBNP) cutoffs for diagnosis of heart failure (HF) is needed. OBJECTIVES This study sought to evaluate the diagnostic performance of NT-proBNP for acute HF in patients with dyspnea in the emergency department (ED) setting. METHODS Dyspneic patients presenting to 19 EDs in North America were enrolled and had blood drawn for subsequent NT-proBNP measurement. Primary endpoints were positive predictive values of age-stratified cutoffs (450, 900, and 1,800 pg/ml) for diagnosis of acute HF and negative predictive value of the rule-out cutoff to exclude acute HF. Secondary endpoints included sensitivity, specificity, and positive (+) and negative (-) likelihood ratios (LRs) for acute HF. RESULTS Of 1,461 subjects, 277 (19%) were adjudicated as having acute HF. The area under the receiver-operating characteristic curve for diagnosis of acute HF was 0.91 (95% confidence interval [CI]: 0.90 to 0.93; p < 0.001). Sensitivity for age stratified cutoffs of 450, 900, and 1,800 pg/ml was 85.7%, 79.3%, and 75.9%, respectively; specificity was 93.9%, 84.0%, and 75.0%, respectively. Positive predictive values were 53.6%, 58.4%, and 62.0%, respectively. Overall LR+ across age-dependent cutoffs was 5.99 (95% CI: 5.05 to 6.93); individual LR+ for age-dependent cutoffs was 14.08, 4.95, and 3.03, respectively. The sensitivity and negative predictive value for the rule-out cutoff of 300 pg/ml were 93.9% and 98.0%, respectively; LR - was 0.09 (95% CI: 0.05 to 0.13). CONCLUSIONS In acutely dyspneic patients seen in the ED setting, age-stratified NT-proBNP cutpoints may aid in the diagnosis of acute HF. An NT-proBNP < 300 pg/ml strongly excludes the presence of acute HF. (c) 2018 by the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available